Related Experiment Video

Updated: May 3, 2026

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
08:34

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis

Published on: June 3, 2016

17.2K

Decreased fetal pre-adipocyte factor-1 in pregnancies complicated by gestational diabetes mellitus

Jie Li1, Qiuyuan Zhu1, Hanzhi Wang1

  • 1Women's Hospital, School of Medicine, Zhejiang University, Key Laboratory of Reproductive Genetics, Ministry of Education, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|February 13, 2014
PubMed

Insights

Serum pre-adipocyte factor-1 (pref-1) levels are lower in fetuses of mothers with gestational diabetes mellitus (GDM). This finding may impact the child's future metabolic health.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Perinatal Medicine

Background:

  • Serum pre-adipocyte factor-1 (pref-1) inhibits adipocyte differentiation and is linked to metabolic disease risk.
  • Elevated pref-1 is observed in small for gestational age fetuses.
  • Gestational diabetes mellitus (GDM) may alter fetal pref-1 concentrations.

Purpose of the Study:

  • To investigate fetal pre-adipocyte factor-1 (pref-1) concentrations in pregnancies complicated by gestational diabetes mellitus (GDM).

Main Methods:

  • Umbilical cord blood samples were collected from fetuses of mothers with GDM (n=37) and normal pregnancies (n=45).
  • Pref-1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA).
  • Fetal birth weights were recorded and compared between groups.

Main Results:

  • Fetal serum pref-1 concentrations were significantly lower in the GDM group (16.12±6.48 μg/l) compared to controls (22.09±7.22 μg/l; P=0.001).
  • Fetuses from GDM pregnancies exhibited significantly higher birth weights (3567±544 g) than controls (3253±370 g; P=0.003).

Conclusions:

  • Gestational diabetes mellitus is associated with decreased fetal pref-1 concentrations.
  • These alterations in pref-1 may have implications for the offspring's long-term metabolic health.
  • Further research is warranted to explore the link between GDM, fetal pref-1, and metabolic outcomes.
Abstract

Keywords:
FetusGestational diabetesMetabolic diseasesPreadipocyte factor-1

More Related Videos

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator06:08

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

2.8K
Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring06:11

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Published on: May 17, 2024

1.3K

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and...
24
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K